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Anticoagulant Prescribing for Non-Valvular Atrial Fibrillation in the
Veterans Health Administration
Adam J. Rose, MD, MSc; Robert Goldberg, PhD; David D. McManus, MD, ScM; Alok Kapoor, MD, MSc; Victoria Wang, BA;
Weisong Liu, PhD; Hong Yu, PhD
Background-—Direct acting oral anticoagulants (DOACs) theoretically could contribute to addressing underuse of anticoagulation
in non-valvular atrial fibrillation (NVAF). Few studies have examined this prospect, however. The potential of DOACs to address
underuse of anticoagulation in NVAF could be magnified within a healthcare system that sharply limits patients’ exposure to out-of-
pocket copayments, such as the Veterans Health Administration (VA).
Methods and Results-—We used a clinical data set of all patients with NVAF treated within VA from 2007 to 2016 (n=987 373).
We examined how the proportion of patients receiving any anticoagulation, and which agent was prescribed, changed over time.
When first approved for VA use in 2011, DOACs constituted a tiny proportion of all prescriptions for anticoagulants (2%); by 2016,
this proportion had increased to 45% of all prescriptions and 67% of new prescriptions. Patient characteristics associated with
receiving a DOAC, rather than warfarin, included white race, better kidney function, fewer comorbid conditions overall, and no
history of stroke or bleeding. In 2007, before the introduction of DOACs, 56% of VA patients with NVAF were receiving
anticoagulation; this dipped to 44% in 2012 just after the introduction of DOACs and had risen back to 51% by 2016.
Conclusions-—These results do not suggest that the availability of DOACs has led to an increased proportion of patients with NVAF
receiving anticoagulation, even in the context of a healthcare system that sharply limits patients’ exposure to out-of-pocket
copayments. ( J Am Heart Assoc. 2019;8:e012646. DOI: 10.1161/JAHA.119.012646.)
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N ew-onset atrial fibrillation is estimated to affect severalhundred thousand American adults annually, with
7 million prevalent cases in the United States.1 Atrial
fibrillation is a leading cause of morbidity and mortality
worldwide2 and is a major risk factor for ischemic stroke.3 For
many years, warfarin was the only oral agent available for
long-term anticoagulation for patients with various prothrom-
botic conditions, including atrial fibrillation. The management
of many patients with atrial fibrillation has been changing
in recent years, however, because of the approval of
direct-acting oral anticoagulants (DOACs) for stroke preven-
tion in patients with non-valvular atrial fibrillation (NVAF).4
DOACs do not require the frequent laboratory testing or dose
titrations that are needed to effectively manage patients with
NVAF who are treated with warfarin, a therapy that is
associated with considerable patient burden. The proportion
of patients with NVAF who are prescribed DOACs has
increased dramatically in the United States, Canada, and
Europe since their introduction almost a decade ago.4–13
Based on data from US registries, only half of eligible
patients with NVAF receive anticoagulation for stroke pre-
vention,14 despite the fact that the benefits of anticoagulation
frequently outweigh the risks of treatment.15,16 DOACs could
increase the number of patients willing to receive oral
anticoagulation for stroke prevention since many patients
with NVAF decline warfarin-therapy owing to the frequency of
laboratory monitoring, the possibility of drug-drug interac-
tions, and dietary restrictions.17 Few studies to date, however,
have examined how the introduction of DOACs may have
changed the overall rate of anticoagulation for patients with
AF. The few studies that have been completed, however,
suggest modest changes or no change, perhaps as a result of
the high out-of-pocket costs associated with DOAC therapy.5
The influence of DOACs on the rate of anticoagulation for
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patients with AF, and the question of which medications are
used for which patients, may be different in a system that
sharply limits out of pocket costs for expensive medications,
such as the Veterans Health Affairs (VA) system.18
The primary objective of this large observational study was
to describe recent decade long trends (2007–2016) in the
prescribing of DOACs and warfarin among patients with NVAF
treated in a system that limits out-of-pocket medication costs
to no more than $9/month. Our secondary study objective
was to describe the characteristics of patients with NVAF
likely to be treated with specific anticoagulant regimens
during the years under study.
Methods
Data Set
We used data from the VA Corporate Data Warehouse, a
source that includes patient demographics, diagnosis codes,
dates of service, laboratory test results, and medications
dispensed. Using diagnosis codes, we identified all patients
treated in the VA system with a diagnosis of NVAF between
January 1, 2007, and December 30, 2016. Patients were
considered to have NVAF if they had International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) code 427.31 or ICD-10-CM codes I48.xx, and did not
have one of the ICD codes listed for valvular heart disease in
Table 1. We also varied the definition of what constituted
valvular heart disease, ranging from not excluding any
patients for this reason to a much broader definition of
valvular heart disease encompassing any sort of regurgitation,
stenosis, repair, or replacement of any valve, for any reason.
The sample size changed somewhat because of these choices
(on the order of 10%), but the results of all analyses otherwise
remained virtually identical.
The study was approved by the Institutional Review Boards of
the Bedford VA Medical Center, RAND Corporation, and the
University of Massachusetts Medical School, with a waiver of
informed consent. Because of the sensitive nature of VA data, they
are only available for research by application, and in cooperation
with a VA-based researcher. Inquiresmay be sent to virec@va.gov.
Analytic code is available from the authors upon request.
Dependent Variable—Receipt of Anticoagulant
Therapy
We characterized which patients with NVAF received antico-
agulation within the VA system, based on having received at
least 30 total days’ supply of warfarin or a DOAC from a VA
pharmacy. Of those who were prescribed anticoagulant
therapy, we characterized which patients received a DOAC
as opposed to warfarin, and among those who received a
DOAC, which DOAC. Patients who received both warfarin and
a DOAC were considered to have received the one they
received for more days; in the event of similar usage rates,
they were considered to have received the most recently
dispensed drug. The DOACs were first included in the VA
formulary in Fiscal Year 2011. During the years under
investigation, there were 3 DOACs available from VA
pharmacies, namely apixaban, dabigatran, and rivaroxaban.
Independent Variables—Patient-Level
Characteristics
We characterized patients based on their age, sex, body mass
index, and region of the United States (Northeast, Southeast,
West, and Midwest). We characterized whether patients had a
history of certain comorbid conditions (heart failure, hyper-
tension, vascular disease, diabetes mellitus, prior bleeding,
and prior stroke) using a 1-year look-back period19 and based
on the ICD codes in Table 1. For each patient, we computed a
CHADS-VASc stroke risk score,20,21 based on the demo-
graphics and comorbid conditions mentioned above. We
calculated patient’s estimated glomerular filtration rate from
laboratory creatinine findings and other parameters using the
Modification of Diet in Renal Disease formula.22 This formula
was selected because of its compatibility with the creatinine
assays used in the VA system throughout the study period,
and with the data elements available in the VA data set. For
patients with multiple creatinine values during the study
period, we used the most recent value. We also calculated a
count of Elixhauser Comorbidities for each patient, using
diagnostic codes reported as part of hospital and ambulatory
encounters.23
Clinical Perspective
What Is New?
• In the Veterans Health Administration, in 2016, patient-level
predictors of receiving a direct-acting anticoagulant for non-
valvular atrial fibrillation, as opposed to warfarin, included
intact renal function, lack of prior stroke, fewer comorbid
conditions, and living in the Northeast region.
What Are the Clinical Implications?
• The availability of direct-acting anticoagulants has not led to
an increased proportion of patients with non-valvular atrial
fibrillation receiving anticoagulation, even in the context of a
healthcare system that sharply limits patients’ exposure to
out-of-pocket copayments.
• Clinicians should choose the optimal medication for each
patient based on clinical considerations, and consistent with
clinical guidelines.
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Data Analyses
We compared the characteristics of patients who received
oral anticoagulation from the VA with those who did not
receive anticoagulation, using multivariable adjusted logistic
regression analyses. Among Veterans with NVAF with docu-
mentation that they received anticoagulation within the VA,
we compared the characteristics of those who received a
Table 1. ICD Codes to Define Valvular Heart Disease, Comorbid Conditions, and Stroke Risk Factors
ICD-9-CM ICD-10-CM
Valvular heart disease—
diagnosis codes
394.0 Mitral stenosis
394.2 Mitral stenosis with insufficiency
396.1 Mitral stenosis with aortic insufficiency
396.8 Mitral and aortic multiple valvular disease
396.9 Mitral and aortic valve disease NOS
746.5 Congenital mitral stenosis
V43.3 Heart valve replacement NEC
I05.0 Rheumatic mitral stenosis
I05.2 Rheumatic mitral stenosis with insufficiency
I08.0 Rheumatic disorders of both mitral and aortic valves
I08.1 Rheumatic disorders of both mitral and tricuspid valves
I08.3 Combined rheumatic disorders of mitral, aortic,
and tricuspid valves
I08.8 Other rheumatic multiple valve diseases
I08.9 Rheumatic multiple valve disease, unspecified
I09.81 Rheumatic heart failure
I34.2 Nonrheumatic mitral valve stenosis
Q23.2 Congenital mitral stenosis
Q23.8 Other congenital malformations of aortic and mitral valves
Q23.9 Congenital malformations of aortic and mitral valves,
unspecified
Z95.2 Presence of prosthetic heart valve
Valvular heart disease—
procedure codes
35.02 Closed mitral valvotomy
35.12 Open mitral valvuloplasty
35.20 Replace heart valve NOS
35.22 Replace aortic valve NEC
35.24 Replace mitral valve NEC
35.26 Replace pulmonary valve NEC
35.28 Replace tricuspid valve NEC
02QG Repair of mitral valve
02RF Replacement of aortic valve
02RG Replacement of mitral valve
02RH Replacement of pulmonary valve
02RJ Replacement of tricuspid valve
Heart failure 398.91, 402.x, 404.01, 404.11, 404.03, 428.x I42.9, I50.x
Hypertension 401.x, 402.x, 403.x, 404.x, 405.x, 437.2 I50.30, I50.40, I50.9, N03.9, N18.1, N18.2, N18.3, N18.4, N18.5,
N18.6, N18.9, N19, Z99.2, I10, I11, I11.0, I11.9,
I12, I12.0, I12.9, I13, I13.0, I13.1, I13.10, I13.11, I13.2,
I15, I15.0, I15.1, I15.2, I15.8, I15.9, I16, I16.0, I16.1, I16.9
Vascular disease 410.x, 411.x, 412, 440.x, 441.x, 443.1, 443.89 H91.90, G40.909, E11.9, N28.9, I21.x-I24.x, I70.x
Diabetes mellitus 249.x, 250.x, 357.2, 362, 366.41 B35.1, E03.9, E23.2, E27.49, E66.9, E78.1, E78.6, G56.00,
H21.1X9, H33.40, H34.9, H35.049, H40.9, H42, H43.10,
H47.099, H47.20, H54.0, H54.10, H54.7, H91.90, I10,
I12.0, I12.9, I70.209, K31.84, L03.039, L03.119, L89.509,
L89.609, L97.209, L97.309, L97.409, L97.509, L97.519,
L97.529, L97.909, L97.919, L97.929, L98.499, M54.14,
M54.16, M86.9, N18.1, N18.2, N18.3, N18.4, N18.5,
N18.6, N18.9, N52.1, R19.7, R80.9, Z79.4, Z99.2,
E08-E13
Prior bleeding 423.0, 430, 431, 432.x, 455.2, 455.5, 455.8, 456.0, 456.2,
459.0, 530.7, 530.82, 531.01, 531.41, 531.61, 532.01,
532.21, 532.41, 532.61, 533.21, 533.4, 534.41, 535.01,
535.11, 535.31, 535.41, 535.51, 535.61, 537.83, 537.84,
562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85,
578.x, 596.7, 599.7, 719.1x, 782.7, 784.7, 784.8, 786.3
I312, I609, I619, I621, I6200, I629, K648, K644, K648,
I8501, I8511, R58, K226, K228, K250, K254, K256, K260, K262,
K264, K266, K272, K274, K284, K2901, K2941,
K2951, K2941, K2951, K2961, K2971, K2991, K2981, K31811,
K3182, K5711, K5713, K5731, K5733, K661,
K625, K5521, K920, K921, K922, N3289, R319, R310,
R312, R311, M2500, M25019, M25029, M25039,
M25049, M25059, M25069, M25073, M25076, M2508, M2500,
R233, R040, R041, R042, R049
Prior stroke 433.01, 433.1, 433.11, 433.21, 433.31, 433.81, 433.91,
434.01, 434.11, 434.91, 435.x, 436
G93.49, I67.89, G45.x, I63.x, I74.x
ICD-9-CM indicates International Classification of Diseases, Ninth Revision, Clinical Modifications; ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modifications;
NEC is not elsewhere classifiable.
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DOAC with those who received warfarin with similar analytic
approaches. We also calculated temporal trends with regard
to the receipt of new (incident) anticoagulants in patients with
newly diagnosed NVAF and prevalent use (across the entire
population of patients with prevalent NVAF). All analyses were
conducted using SAS, version 9.4 (SAS Corporation, Cary,
NC).
Results
Study Population Characteristics
During the decade-long period under study (2007–2016),
there were a total of 987 373 VA patients with a diagnosis of
NVAF (Table 2). The mean age of these patients was
76 years, 98% were men, and 86% were white. The majority
of patients (88%) had a CHADS-VASc score of ≥2, corre-
sponding to an appreciable risk of stroke.
Trends in Anticoagulation Use
Overall, during the 10-year period under study, 47% of
patients with NVAF received some form of anticoagulation
therapy from the VA (Figure 1). The proportion who were
treated with anticoagulation was 56% in our initial study year
of 2007, declined during the middle of the study period (2012:
44%), and by 2016 the proportion who were treated with
anticoagulation had increased to 51%.
Table 2. Patient-Level Factors Associated With the Receipt of
Anticoagulation Therapy From the Veterans Health
Administration Among Patients With Non-Valvular Atrial
Fibrillation, 2007 to 2016
Characteristic
Received
Anticoagulation
From VA
(n=405 516)
Did Not Receive
Anticoagulation
From VA
(n=581 857)
Adjusted
Odds Ratio*
Age (mean), y 75.7 77.1 1.00 (1.00–1.00)
Age, y
<65 12 13 REF
65 to 74 35 28 1.26 (1.23–1.29)
75 to 84 30 29 1.15 (1.11–1.19)
≥85 23 31 0.89 (0.85–0.93)
Sex
Women 2 2 REF
Men 98 98 1.19 (1.15–1.23)
Race
White 85 86 REF
Black 9 8 1.09 (1.08–1.11)
Other 6 6 0.98 (0.96–1)
Geographic region
Northeast 15 19 REF
Midwest 25 24 1.23 (1.21–1.25)
West (including
Pacific)
21 20 1.26 (1.24–1.28)
South 39 38 1.16 (1.14–1.18)
Body mass index, kg/m2
<25 24 28 REF
25 to 29.9 31 31 1.03 (1.02–1.05)
30 to 34.9 22 18 1.06 (1.04–1.08)
≥35 19 12 1.11 (1.07–1.14)
Comorbid conditions†
Heart failure 20 17 1.19 (1.17–1.2)
Hypertension 70 68 0.97 (0.96–0.99)
Vascular
disease
15 17 0.80 (0.79–0.81)
Diabetes
mellitus
40 38 0.86 (0.85–0.87)
Prior bleeding 5 6 0.83 (0.81–0.84)
Prior stroke 9 7 1.30 (1.27–1.33)
CHA2DS2-VASc Score, %
0 to 1 9 9 0.79 (0.77–0.82)
2 to 4 75 73 1.04 (1.02–1.07)
5 to 9 14 14 REF
Continued
Table 2. Continued
Characteristic
Received
Anticoagulation
From VA
(n=405 516)
Did Not Receive
Anticoagulation
From VA
(n=581 857)
Adjusted
Odds Ratio*
eGFR categories (%), in units of mL/min per 1.73 m2
<30 8 9 1.08 (1.06–1.1)
30 to 44 14 15 1.13 (1.11–1.15)
45 to 59 17 17 1.11 (1.1–1.13)
≥60 59 50 REF
Elixhauser comorbidities
0 to 2 28 29 REF
3 to 4 35 34 0.96 (0.94–0.97)
≥5 31 29 0.92 (0.91–0.94)
Percentages are shown except as otherwise noted. All statistical comparisons in the
table are significant at the P<0.001 level. eGFR indicates estimated glomerular filtration;
VA, Veterans Health Administration.
*Odds ratio for receiving anticoagulation from Veterans Health Administration vs not
receiving. Adjusted for all other variables in the table.
†For each condition, the reference category is patients without the condition.
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Patient Characteristics Associated With the
Receipt of Anticoagulation
Several patient-level characteristics were associated with the
receipt of anticoagulation (Table 2). In the multivariable
adjusted model, patients with heart failure or prior stroke
were more likely to receive anticoagulation than those without
these conditions, whereas patients with diabetes mellitus or
prior bleeding were less likely to receive anticoagulation than
respective comparison groups. Patients with a CHADS-VASc
score of 0 to 1, for whom anticoagulation is generally not
recommended, were less likely to receive anticoagulation
(adjusted odds ratio [AOR], 0.79). Patients with impaired renal
function, as compared with those with normal renal function,
were slightly more likely to receive anticoagulation.
Trends in the Use of Direct Acting Oral
Anticoagulants Versus Warfarin
All analyses from this point on will focus on the subset of
patients with NVAF who received a first prescription for an
oral anticoagulant from the VA between 2011 and 2016,
which is the period when DOACs were in use—a total of
45 753 unique patients (Table 3). During this period, 81% of
patients who received anticoagulation from the VA were
treated with warfarin, while the remainder received a DOAC
(Figure 1). The proportion of anticoagulation recipients who
received a DOAC was only 2% in 2011; by 2016, it had
increased to 45%. For new prescriptions, the trend was even
more pronounced. In 2011, only 4% of new prescriptions for
anticoagulants in the VA were for a DOAC; this proportion
increased to 67% in 2016.
Patient Characteristics Associated With the
Receipt of Direct Acting Oral Anticoagulants
Versus Warfarin
We examined the patient sociodemographic and clinical
characteristics associated with the receipt of a DOAC versus
warfarin, among all patients who received oral anticoagulation
from the VA for NVAF. This analysis was limited to the 45 753
patients who received a first prescription for an oral
anticoagulant from the VA during 2016, the final year of our
study (Table 3). Age and sex were not important determinants
of receiving a DOAC as opposed to warfarin. DOAC use varied
by region, with the highest rate of use in the Northeast and
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
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Figure 1. Trends in the receipt of direct oral anticoagulants (DOAC) and warfarin in patients with
prevalent non-valvular atrial fibrillation (AFib) in the Veterans Health Administration.
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the lowest in the Midwest (adjusted odds ratio, or AOR, 0.80
compared with the Northeast). Patients of black race were
less likely to receive a DOAC than those of white race
(AOR=0.86). Patients with heart failure, prior bleeding, and
prior stroke were less likely to receive a DOAC than those
without these conditions (AOR=0.82, 0.77, and 0.74, respec-
tively). Patients with >2 Elixhauser comorbid conditions were
less likely to receive a DOAC; for example, those with ≥5
conditions had an AOR of 0.68 compared with those with ≤2
conditions. Finally, impaired kidney function was associated
with a lower likelihood of DOAC use, a with larger effect sizes
as the degree of kidney function became more severe (AOR
for estimated glomerular filtration rate <30=0.20, compared
with estimated glomerular filtration rate ≥60).
Trends in DOAC Use
We examined trends in DOAC use across the VA system
between 2011 and 2016 (Figure 2). Dabigatran accounted for
all of the DOAC prescriptions in 2010 and 2011, as it was the
only DOAC available. Beginning in 2012, about the time of
their release to market, apixaban and rivaroxaban began to be
prescribed and the proportion of dabigatran-treated patients
declined. By 2016, 53% of new DOAC prescriptions were for
apixaban, 28% were for rivaroxaban, and only 20% were for
dabigatran.
Discussion
The results of this large observational study suggest changing
practice patterns in the types of anticoagulant therapies used
for stroke prevention in patients with new onset or long
standing NVAF during the years under study. Although
Table 3. Patient-Level Factors Associated With Receiving a
DOAC From the Veterans Health Administration for Atrial
Fibrillation During 2016, as Compared With Receiving
Warfarin, Among Those Who Received an Initial Prescription
for an Oral Anticoagulant During That Year
Characteristic
Received
a DOAC
(n=30 733)
Received
Warfarin
(n=15 020)
Adjusted Odds
Ratio* to Receive
a DOAC
Age (mean), y 73.7 72.2 
Age (y) (%)
<65 14 18 REF
65 to 74 43 46 0.96 (0.87–1.05)
75 to 84 28 24 1.00 (0.85–1.17)
≥85 15 12 1.13 (0.91–1.40)
Men, % 98 98 0.94 (0.79–1.11)
Race
White 87 83 REF
Black 8 11 0.86 (0.80–0.93)
Other 5 6 0.97 (0.88–1.06)
Geographic region
Northeast 16 14 REF
Midwest 24 26 0.8 (0.75–0.86)
West (including
Pacific)
21 21 0.85 (0.79–0.92)
South 39 39 0.93 (0.87–0.99)
BMI, kg/m2
<25 19 19 REF
25 to 29.9 33 29 1.09 (1.01–1.17)
30 to 34.9 26 25 1.07 (0.97–1.18)
>35 20 24 1.05 (0.91–1.2)
Key comorbid conditions†
Heart failure 16 23 0.82 (0.77–0.88)
Hypertension 74 76 1.22 (1.14–1.3)
Vascular disease 28 35 0.90 (0.85–0.95)
Diabetes mellitus 66 70 0.96 (0.91–1.02)
Prior bleeding 5 7 0.77 (0.71–0.84)
Stroke 6 9 0.74 (0.67–0.81)
CHA2DS2-VASc Score, %
0 to 1 9 8 1.02 (0.87–1.19)
2 to 4 71 66 0.99 (0.91–1.08)
5 to 9 18 23 REF
eGFR categories (%), in units of mL/min per 1.73 m2
<30 2 9 0.20 (0.18–0.23)
30 to 44 9 9 0.70 (0.64–0.76)
45 to 59 16 14 0.86 (0.81–0.92)
Continued
Table 3. Continued
Characteristic
Received
a DOAC
(n=30 733)
Received
Warfarin
(n=15 020)
Adjusted Odds
Ratio* to Receive
a DOAC
≥60 71 67 REF
Elixhauser comorbidities
0 to 2 27 22 REF
3 to 4 37 32 0.94 (0.88–1.00)
≥5 28 41 0.68 (0.63–0.73)
Percentages are shown except as otherwise noted. BMI indicates body mass index;
DOAC indicated direct-acting oral anticoagulants; eGFR, estimated glomerular filtration.
*Adjusted for all the other variables in the table.
†For each condition, the reference category is patients without the condition.
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Figure 2. Trends in which medication was selected, among all recipients of direct oral anticoagulants
(DOAC) for non-valvular atrial fibrillation (AF) in the Veterans Health Administration. A, Among new
prescriptions (incident), (B) Among all prescriptions (prevalent).
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warfarin therapy remained the most commonly used oral
anticoagulant for patients with NVAF throughout the study
period, there was a progressive increase in the use of DOACs
over time. By 2016, although the prevalent rate of warfarin
use remained higher than for all DOACs combined, the
proportion of new anticoagulation prescriptions for a DOAC
was 67%. These findings are consistent with recent US
registry data showing that more than half of patients with
NVAF receiving anticoagulation are treated with warfarin, but
that the majority of new prescriptions are for a DOAC.5
One of the promises of DOACs has been to expand the
number of patients with NVAF who are willing and able to
receive anticoagulation therapy for stroke prevention. Similar
to the results of previous studies,5 we did not detect a
meaningful change in the percentage of patients with NVAF
who received anticoagulation after the introduction of DOACs.
This percentagewas 56% in 2007, our first year of data, and 51%
in 2016, 5 years after DOACs first became available in the VA.
These data suggest that DOACs have not increased the overall
proportion of anticoagulation-eligible patients who actually
received therapy for stroke prevention in AF, even in a system
that provides equal access to care and limits copayments to no
more than $9 per medication per month—features that would
tend to encourage greater use of these agents, because
patients are largely shielded from out-of-pocket costs. This
finding suggests that factors other than out-of-pocket drug
costs may more strongly influence anticoagulation decision-
making than has previously been appreciated.
In fact, there is a rich literature about the reasons why
approximately half of patients with NVAF do not receive
anticoagulation therapy. One particularly illustrative chart-
review study from the pre-DOAC era24 found that 55% of
patients with NVAF were receiving anticoagulation, a propor-
tion consistent with the published literature.14 Of the
remainder, most had documented reasons for not receiving
anticoagulation: most commonly, gastrointestinal bleed, an
expectation that atrial fibrillation would be transient, and
increased risk of falls. Only 7.1% of the patients lacked a
documented reason for omitting anticoagulation. It is worth
noting that patient refusal to take warfarin because of
inconvenience was not a prominent reason for its omission in
this study. Therefore, it may not be terribly surprising that the
advent of a medication that markedly decreases inconve-
nience may not have increased the proportion of patients with
NVAF who receive anticoagulation.
Our study also examined some of the patient-level variables
that may influence who receives a DOAC versus warfarin. Some
of the predictors of receiving a DOAC in our analyses seem
evidence based. For example, we found markedly lower rates of
use of DOACs among NVAF patients with increasing levels of
renal impairment. DOACs are relatively or absolutely con-
traindicated in the presence of significant chronic renal
insufficiency or end-stage renal disease.25–27 Other findings,
such as a lower likelihood of receiving DOAC therapy among
those with prior stroke or prior bleeding, and especially among
patients with a greater number of comorbid conditions, are less
evidence-based, although they are in agreement with the
findings of previous observational studies.4–7,28–30 Finally,
while the effect size is rather small, it is noteworthy that black
patients were less likely than whites to receive DOACs, even
after controlling for covariates such as kidney function, and
even in the context of a system that provides equal access to
care, central guidance on how to use medications, and low
copayments. Several previous studies in non-VA settings have
also shown that white patients are more likely to receive a
DOAC.28–31 Finding this disparity in the VA system, where
access and cost issues are largely eliminated, suggests some
other provider or patient predisposition against the use of
DOACs.
This study has several important strengths, including the size
and detail of the database, and the availability of a decade of
longitudinal data in which wewere able to examine trends in the
receipt of different anticoagulant therapies used for the
prevention of stroke in patients with AF. However, this study
also has several limitations that need be kept in mind in the
interpretation of the present results. Based on our prior work,32
we expect that we might have misspecified the anticoagulation
status of 10% of patients who received warfarin outside of the
VA system. In contrast, for patients eligible for VA benefits,
receiving a DOAC outside the VA would be unusual, since VA
copayments for medications are limited to no more than $9/
month,18 whereas out-of-pocket payments for VA patients
receiving DOACs outside the VA system are often ≥$100/
month.6 Another potential limitation is that our study does not
contain a counterfactual. While we did not find that the
proportion of patients receiving anticoagulation increased in
the VA after the introduction of DOACs, we cannot know for
sure if that proportion would have been still lower had the
DOACs not become available during this period.
Another limitation is that VA patients are mostly men and
have a high burden of comorbid illness and social need.
However, our study used data from the nation’s largest
integrated healthcare system to examine trends in DOAC use
and uptake in a system that sharply limits the size of
copayments. Thus, our results may be applicable in similar
situations, such as nations that provide a high level of medical
benefits.
Finally, our estimates for patient-level predictors of
receiving a DOAC, as opposed to warfarin, used all new
anticoagulant prescriptions from 2016. We used this year as it
was the latest year of data available to us, and because the
trend line of DOAC prescriptions (Figure 1) was beginning to
level off by this time. However, we acknowledge that patterns
of anticoagulant prescribing had not completely stabilized by
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2016, and indeed may not have stabilized to date. Therefore,
it is unavoidable that the estimates in Table 3 reflect 2016
patterns of practice, and may not precisely reflect what would
have been found in earlier or later years. In addition,
estimates based on only 1 year of data may be less robust,
although the sample size of >45 000 for this analysis is likely
sufficient to ensure stable estimates.
Conclusion
Our study does not suggest that the introduction of DOACs led
to an increase in the proportion of patients with NVAF receiving
anticoagulation in the VA setting. In the VA, DOACs appear to
be given preferentially to patients who have fewer comorbid
conditions, who do not have a history of prior bleeding or
stroke, and who are white. These findings run counter to what
best practices might suggest as ideal, including recently
released management guidelines for atrial fibrillation.21 Almost
a decade after the introduction of DOACs, we continue to use
them rather haphazardly, even in a setting where their direct
cost to patients is sharply curtailed. Our results suggest a need
to rationalize our use of DOACs to maximize their benefit.
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